Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Capecitabine (DB01101)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06853769	Neoadjuvant Therapy for Locally Advanced Rectal Cancer	Treatment	Anlotinib (DB11885) Capecitabine (DB01101) Oxaliplatin (DB00526) Penpulimab (DB16747)
NCT06547385	Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) ONO-4578 (DB22389) Oxaliplatin (DB00526)
NCT06328738	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer	Treatment	Capecitabine (DB01101) ELVN-002 (DB22140) Eribulin (DB08871) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Trastuzumab (DB00072)
NCT05704985	Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors	Treatment	Capecitabine (DB01101) Carboplatin (DB00958) DK210 (DB24308) Fluorouracil (DB00544) Nivolumab (DB09035) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT05464030	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Precemtabart tocentecan (DB22490)
NCT05609370	A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer	Treatment	Alcestobart (DB28487) Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Tislelizumab (DB14922)